Darolutamide’s low blood–brain barrier penetration may reduce the incidence of fatigue and cognitive impairment compared with other androgen receptor inhibitors (Kyriakopoulos et al., 2018; Fizazi et al., 2019). This evidence concerns the gene AR and Cognitive impairment.